CA3230314A1 - Solid forms of bcl-2 inhibitors, method of preparation, and use thereof - Google Patents

Solid forms of bcl-2 inhibitors, method of preparation, and use thereof Download PDF

Info

Publication number
CA3230314A1
CA3230314A1 CA3230314A CA3230314A CA3230314A1 CA 3230314 A1 CA3230314 A1 CA 3230314A1 CA 3230314 A CA3230314 A CA 3230314A CA 3230314 A CA3230314 A CA 3230314A CA 3230314 A1 CA3230314 A1 CA 3230314A1
Authority
CA
Canada
Prior art keywords
crystalline form
compound
ray powder
crystalline
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3230314A
Other languages
English (en)
French (fr)
Inventor
Desheng YU
Gongyin SHI
Hai Xue
Yunhang GUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
BeOne Medicines I GmbH
Original Assignee
BeiGene Switzerland GmbH
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeiGene Switzerland GmbH, Beigene Ltd filed Critical BeiGene Switzerland GmbH
Publication of CA3230314A1 publication Critical patent/CA3230314A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3230314A 2021-08-31 2022-08-31 Solid forms of bcl-2 inhibitors, method of preparation, and use thereof Pending CA3230314A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/115718 2021-08-31
CN2021115718 2021-08-31
PCT/CN2022/116084 WO2023030363A1 (en) 2021-08-31 2022-08-31 Solid forms of bcl-2 inhibitors, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
CA3230314A1 true CA3230314A1 (en) 2023-03-09

Family

ID=85410866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3230314A Pending CA3230314A1 (en) 2021-08-31 2022-08-31 Solid forms of bcl-2 inhibitors, method of preparation, and use thereof

Country Status (11)

Country Link
US (1) US20240317743A1 (https=)
EP (1) EP4396180A4 (https=)
JP (1) JP2024530315A (https=)
KR (1) KR20240054327A (https=)
CN (1) CN118215660A (https=)
AU (1) AU2022336557A1 (https=)
CA (1) CA3230314A1 (https=)
IL (1) IL311106A (https=)
MX (1) MX2024002465A (https=)
TW (1) TW202328125A (https=)
WO (1) WO2023030363A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
WO2026002056A1 (en) 2024-06-26 2026-01-02 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138588A2 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2668180B1 (en) * 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
SG11202009933WA (en) * 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Also Published As

Publication number Publication date
JP2024530315A (ja) 2024-08-16
WO2023030363A1 (en) 2023-03-09
KR20240054327A (ko) 2024-04-25
CN118215660A (zh) 2024-06-18
AU2022336557A1 (en) 2024-03-21
EP4396180A4 (en) 2025-07-09
TW202328125A (zh) 2023-07-16
EP4396180A1 (en) 2024-07-10
US20240317743A1 (en) 2024-09-26
IL311106A (en) 2024-04-01
MX2024002465A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
ES2985767T3 (es) Formas en estado sólido de rucaparib y de sales de rucaparib
WO2025019688A2 (en) Crystalline forms of salts of adagrasib
JP2015180679A (ja) ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
KR20210013554A (ko) Tlr7/tlr8 억제제의 결정질 형태
US20240317743A1 (en) Solid Forms of BCL-2 Inhibitors, Method of Preparation, and Use Thereof
JP2021504297A (ja) Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態
WO2016026974A1 (en) Oxalate salt of ruxolitinib
WO2016026975A1 (en) Salt of (r)-3-(4-(7h-pyrrolo [2,3-d] pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
US11230559B2 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate
EP4222148A1 (en) Crystalline form of tegavivint, method of preparation, and use thereof
US12202834B2 (en) Solid state forms of oclacitinib maleate
TW201904954A (zh) 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法
KR20200024302A (ko) 페닐 피리미돈 화합물의 염, 다형체 및 이의 약학 조성물 및 용도
US11267791B2 (en) Highly stable crystalline Eltrombopag monoethanolamine salt form D1
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
CN114026088A (zh) Jak2抑制剂的结晶形式
TW202024087A (zh) 四氫哌喃基胺基－吡咯并嘧啶酮化合物的固體形式
HK40106793A (zh) Bcl-2抑制剂的固体形式、其制备方法及用途
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
CN115515954A (zh) 6-氯-7-(4-(4-氯苄基)哌嗪-1-基)-2-(1,3-二甲基-1h-吡唑-4-基)-3h-咪唑并[4,5-b]吡啶的盐和多晶型形式
WO2017029408A1 (en) Solid state forms of sofosbuvir
CA2944150A1 (en) Polymorphic forms and co-crystals of a c-met inhibitor

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240805

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250805

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20251212

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251212

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260402

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260422